ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment.

Promis Neurosciences Inc. surged 21.37% in premarket trading, with the company announcing that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMN310, the Company’s lead therapeutic candidate in development for the treatment of Alzheimer’s disease (AD). This designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease.